Repare Therapeutics to Present Phase 1 MINOTAUR Data at ESMO GI 2024

Repare Therapeutics Inc. (Nasdaq: RPTX), a prominent clinical-stage precision oncology company, has announced preliminary findings from their Phase 1 MINOTAUR study. This study evaluates lunresertib (RP-6306) in conjunction with FOLFIRI for treating advanced solid tumors. These findings will be presented at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, scheduled from June 26-29 in Munich, Germany.

The poster presentation, titled "Phase 1 Study of the PKMYT1 Inhibitor Lunresertib (Lunre) in Combination with FOLFIRI in Advanced Gastrointestinal (GI) Cancers (MINOTAUR Study)," will be delivered by Zev A. Wainberg from the David Geffen School of Medicine at UCLA. The presentation, identified as 504P, is set for June 27, 2024, at 3:35 PM CEST.

Repare Therapeutics, a leader in the field of precision oncology, leverages its unique synthetic lethality approach to discover and develop innovative cancer treatments. The company's proprietary genome-wide, CRISPR-enabled SNIPRx® platform plays a crucial role in identifying and creating highly targeted therapies that address genomic instability and DNA damage repair mechanisms. 

Currently, Repare Therapeutics' pipeline features several promising candidates in various stages of clinical development. Lunresertib (RP-6306), a PKMYT1 inhibitor, is in Phase 1/2 clinical trials. Another noteworthy candidate is camonsertib (RP-3500), an ATR inhibitor also undergoing Phase 1/2 clinical trials. Additionally, their portfolio includes RP-1664, a PLK4 inhibitor in Phase 1, and RP-3467, a preclinical Polθ ATPase inhibitor program. The company is also working on several undisclosed preclinical programs aimed at broadening their therapeutic offerings.

Repare Therapeutics' innovative approach and strategic use of cutting-edge technologies position it as a frontrunner in the development of precision oncology treatments. Their commitment to addressing unmet needs in cancer therapy is evident through their robust pipeline and ongoing clinical trials. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!